There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Gastric outlet obstruction (GOO) is a mechanical blockage that clinically progresses
based on the degree of obstruction. Patients often experience debilitating symptoms
with intractable nausea, vomiting, and limited peroral intake that can quickly lead
to malnutrition, decreased quality of life, and potential delays in chemotherapy
1
. While surgical gastroenterostomy (SGE) has been the mainstay of treatment with long-term
palliation, it is associated with significant morbidity and mortality that may delay
treatment in the postoperative period
2
. Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) has emerged as an effective
minimally invasive alternative for suboptimal operative candidates
1
. Comparing these techniques is paramount, especially as increased operator experience
with EUS-GE expands and advancements in chemotherapy treatment extends the life expectancy
in this patient population.
In a recent issue of Endoscopy International Open, Jaruvongvanich et al
3
compare the outcomes of patients undergoing EUS-GE, enteral stenting (ES), or SGE
for benign and malignant etiologies of GOO. This was a dual-center retrospective study
of 436 patients with a median follow up of 185.5 days, of which 233 were in the EUS-GE
cohort. Baseline characteristics between EUS-GE and SGE were largely similar, although
the EUS-GE group had higher rates of ascites, peritoneal carcinomatosis, ECOG status,
a malignant indication, and symptomatic GOO. The technical success rate was similar
in all groups. However, the clinical success rate was significantly higher in the
EUS-GE group compared to ES and SGE (98.3% vs 91.6% vs 90.4%,
P
= 0.002) with lower rates of reintervention (0.9% vs 12.2% vs 13.7%,
P
< 0.0001) and median length of stay (LOS) (2 vs 3 vs 5 days,
P
< 0.0001). A subgroup analysis examining the 360 patients with malignant GOO demonstrated
similar findings. There were also lower rates of adverse events in the EUS-GE group
(8.6%) compared to SGE (27.4%) and ES (38.9%). There were limited instances of stent
obstruction, migration, and inadequate stent expansion after EUS-GE. The long-term
outcomes of EUS-GE appear to be reliable, especially in a sicker patient population,
as was the case in this cohort.
This is a well-designed study that advances the current literature supporting the
efficacy and durability of EUS-GE, particularly in sick patients. Yet, before these
data can alter practice management, one must consider that this study did not differentiate
surgical approaches (open and laparoscopic) in their outcomes. Laparoscopic SGE is
now the preferred method because it is associated with improved outcomes, decreased
LOS, and shorter time to resumption of oral intake
4
. Analyzing outcomes should ideally be done in this context, although such a comparison
is limited in a retrospective study. Patients who undergo conversion from laparoscopic
to open approaches will likely have fundamentally different outcomes than those whose
procedures can be completed laparoscopically.
There is selection bias and heterogeneity in all studies to date pertaining to EUS-GE
versus SGE. Patients undergoing EUS-GE are generally sicker with more advanced cancers
and comorbidities
5
. A more focused comparison between laparoscopic SGE and EUS-GE, therefore, may either
blunt or further cement the advantages of a purely endoscopic approach. Prospective
studies comparing these techniques are needed as we continue to define the optimal
role of EUS-GE for GOO.
Publication note
Letters to the editor do not necessarily represent the opinion of the editor or publisher.
The editor and publisher reserve the right to not publish letters to the editor, or
to publish them abbreviated or in extracts.
Gastric outlet obstruction (GOO) can result from benign and malignant causes. Until recently, surgical gastrojejunostomy was the treatment of choice for patient with benign and malignant GOO with a good functional status. Endoscopic placement of luminal self-expandable metal stents is currently widely accepted as the first line of treatment for malignant GOO because of its effectiveness and minimally invasive nature. The main shortcoming of luminal stents is the high incidence of recurrent GOO most commonly because of tumor ingrowth/overgrowth. More recently, endoscopic ultrasound (EUS)-guided gastroenterostomy (EUS-GE) has emerged as an alternative to both luminal stent placement and surgical gastrojejunostomy. Advantages of EUS-GE include its minimally invasive nature, efficacy and low incidence of recurrent GOO in cancer patient. We will describe five different techniques to perform this novel and rapidly evolving procedure using a biflanged, lumen-apposing metal stent and compare benefits and risks of each approach. These approaches include antegrade EUS-GE or 'traditional/downstream' and 'rendezvous' methods, retrograde EUS-GE or 'enterogastrostomy,'17 (EPASS), and antegrade EUS-GE 'direct' method.
Palliative gastrojejunostomy (GJJ) for gastric outlet obstruction (GOO) associated with unresectable advanced gastric cancers (UAGC) is the most commonly used treatment modality, but its indication remains controversial. In this multi-institutions study, we investigated the clinical outcome of GJJ for UAGC and predictors of outcome and survival. A retrospective analysis was performed on 211 patients who underwent palliative GJJ for GOO caused by UAGC from 29 institutions between 2007 and 2009. Operative outcome including postoperative morbidity, mortality, assessment of oral intake by GOO Scoring System (GOOSS) and survival time were recorded. Prognostic factors for overall survival and risk factors for hospital death were investigated by univariate and multivariate analyses. Postoperative oral food intake was recorded in 203 (96 %) patients. The average GOOSS improved from 1.1 at baseline to 2.5 at 1 month after surgery and remained above 2 for up to 6 months. Overall morbidity, 30-day mortality and hospital death rates were 22, 6 and 11 %, respectively. Median survival time was 228 days and 1-year survival rate was 31 %. Poor performance status (PS), prior chemotherapy and high C-reactive protein (CRP) level were significant independent predictors of poor survival. Poor PS and high CRP were also identified as significant risk factors of hospital death. Palliative GJJ is beneficial for GOO caused by UAGC in terms of improvement of oral food intake, with acceptable morbidity and mortality. However, its indication for patients with poor PS, high CRP level, and a history of chemotherapy is less clear.
Background and study aims Gastric outlet obstruction (GOO) is traditionally managed with surgical gastroenterostomy (surgical-GE) and enteral stenting (ES). Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is now a third option. Large studies assessing their relative risks and benefits with adequate follow-up are lacking. We conducted a comparative analysis of patients who underwent EUS-GE, ES, or surgical-GE for GOO. Patients and methods In this retrospective comparative cohort study, consecutive patients presenting with GOO who underwent EUS-GE, ES, or surgical-GE at two academic institutions were reviewed and independently cross-edited to ensure accurate reporting. The primary outcome was need for reintervention. Secondary outcomes were technical and clinical success, length of hospital stay (LOS), and adverse events (AEs). Results A total of 436 patients (232 EUS-GE, 131 ES, 73 surgical-GE) were included. The median duration of follow-up of the entire cohort was 185.5 days (interquartile range 55.25–454.25 days). The rate of reintervention in the EUS-GE group was lower than in the ES and surgical-GE groups (0.9 %, 12.2 %, and 13.7 %, P < 0.0001). Technical success was achieved in 98.3 %, 99.2 %, and 100 % ( P = 0.58), and clinical success was achieved in 98.3 %, 91.6 %, and 90.4 % ( P < 0.0001) in the EUS-GE, ES, and surgical-GE groups, respectively. The EUS-GE group had a shorter LOS (2 days vs. 3 days vs. 5 days, P < 0.0001) and a lower AE rate than the ES and surgical-GE groups (8.6 % vs. 38.9 % vs. 27.4 %, P < 0.0001). Conclusion This large cohort study demonstrates the safety and palliation durability of EUS-GE as an alternative strategy for GOO palliation in select patients.
Publisher:
Georg Thieme Verlag KG
(Rüdigerstraße 14, 70469 Stuttgart, Germany
)
ISSN
(Print):
2364-3722
ISSN
(Electronic):
2196-9736
Publication date
(Electronic):
09
June
2023
Publication date Collection:
June
2023
Publication date PMC-release: 1
June
2023
Volume: 11
Issue: 6
Pages: E566-E567
Affiliations
[1
]Ringgold 12264, Gastroenterology, University of Maryland School of Medicine, Baltimore, United States;
[2
]Ringgold 2331, Gastroenterology, The University of North Carolina at Chapel Hill, Chapel Hill, United
States;
Author notes
Correspondence Dr. Andrew Canakis Ringgold 12264, Gastroenterology, University of Maryland School
of Medicine; BaltimoreUnited States
agcanakis@
123456gmail.com
This is an open-access article distributed under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction
and distribution, for non-commercial purposes only; and use and reproduction, but
not distribution, of adapted material for non-commercial purposes only, provided the
original work is properly cited.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.